Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa S Kierstead

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Vaccine|January 18, 2003
Memory T cells and vaccinesMark T Esser, Rocio D Marchese, Lisa S Kierstead, et al.
The Journal of Experimental Medicine|September 5, 2002
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMCLisa S Kierstead, Sheri Dubey, Barbara Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.
The Journal of Infectious Diseases|November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Vaccine|January 18, 2003
Memory T cells and vaccinesMark T Esser, Rocio D Marchese, Lisa S Kierstead, et al.
The Journal of Experimental Medicine|September 5, 2002
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.
AIDS Research and Human Retroviruses|February 1, 2007
Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMCLisa S Kierstead, Sheri Dubey, Barbara Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2003
MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinomaTomohide Tatsumi, Lisa S Kierstead, Elena Ranieri, et al.
The Journal of Infectious Diseases|November 26, 2009
Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimensDavid M Asmuth, Elizabeth L Brown, Mark J DiNubile, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Pageof 1